ATE373675T1 - Impfstoff gegen pferdearteritisvirus - Google Patents

Impfstoff gegen pferdearteritisvirus

Info

Publication number
ATE373675T1
ATE373675T1 AT02002250T AT02002250T ATE373675T1 AT E373675 T1 ATE373675 T1 AT E373675T1 AT 02002250 T AT02002250 T AT 02002250T AT 02002250 T AT02002250 T AT 02002250T AT E373675 T1 ATE373675 T1 AT E373675T1
Authority
AT
Austria
Prior art keywords
eav
orf
vaccine against
arteritis virus
equine arteritis
Prior art date
Application number
AT02002250T
Other languages
English (en)
Inventor
Matthias Giese
Gholamreza Darai
Original Assignee
Giese Matthias Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giese Matthias Dr filed Critical Giese Matthias Dr
Application granted granted Critical
Publication of ATE373675T1 publication Critical patent/ATE373675T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/5555Muramyl dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/10011Arteriviridae
    • C12N2770/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/10011Arteriviridae
    • C12N2770/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02002250T 2002-01-30 2002-01-30 Impfstoff gegen pferdearteritisvirus ATE373675T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02002250A EP1346998B1 (de) 2002-01-30 2002-01-30 Impfstoff gegen Pferdearteritisvirus

Publications (1)

Publication Number Publication Date
ATE373675T1 true ATE373675T1 (de) 2007-10-15

Family

ID=27771835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02002250T ATE373675T1 (de) 2002-01-30 2002-01-30 Impfstoff gegen pferdearteritisvirus

Country Status (3)

Country Link
EP (1) EP1346998B1 (de)
AT (1) ATE373675T1 (de)
DE (1) DE60222528T2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438969A1 (de) * 2003-01-14 2004-07-21 Universiteit Utrecht Arterivirus Markierungsimpfstoff
CN103028114A (zh) * 2012-12-28 2013-04-10 贵州大学 一种核酸疫苗、核酸疫苗免疫佐剂及制备方法
CN115261519A (zh) * 2022-09-01 2022-11-01 广州海关技术中心 一种用于马病毒性动脉炎病毒核酸检测的rt-raa扩增引物探针、试剂盒和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400656D0 (en) * 1994-01-14 1994-03-09 Mini Agriculture & Fisheries The Vaccine and diagnostic test kit
NL1003579C2 (nl) * 1996-07-12 1998-01-15 Univ Leiden Recombinant DNA-vector.

Also Published As

Publication number Publication date
DE60222528T2 (de) 2008-06-19
EP1346998B1 (de) 2007-09-19
EP1346998A1 (de) 2003-09-24
DE60222528D1 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
MXPA05012827A (es) Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino.
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
GB0318447D0 (en) Therapeutic agents
CY1105746T1 (el) Eνωσεις που επηρεαζουν τη γλυκοκιναση
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
GB0223038D0 (en) Therapeutic compounds
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
GB0225475D0 (en) Therapeutic agents
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
ATE531419T1 (de) Vorrichtung zur verabreichung von therapeutischen mitteln
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
NO20076405L (no) Anvendelse av 24-nor-UDCA
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
SG163598A1 (en) Lawsonia vaccine and methods of use thereof
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
AU9215101A (en) Vaccines containing ribavirin and methods of use thereof
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DE60222528D1 (de) Impfstoff gegen Pferdearteritisvirus
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
SE0200657D0 (sv) Novel Formulation
WO2005091937A3 (en) Compositions useful for the treatment of microbial infections
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties